Tagged with RMAC

Holland Thijs De Kleer, Managing Director, Saco de Visser, Director Cluster Development, discuss recent developments at the Netherlands largest science park and how Leiden has positioned itself as a leader in early stages of development, which creates a great environment to foster innovation. Leiden lies at the center of the Dutch…

research AM Pharma is developing an innovative treatment for acute kidney injury, and minority investor Pfizer recently acquired the option to purchase the firms remaining equity upon the completion of a phase II clinical trial. How competitive do you feel Dutch life sciences in the academic setting are amongst your other…

healthcare Nefarma’s healthcare policy advisor discusses the changes in the Dutch reimbursement system over the previous five years, and the need for greater trust between different healthcare stakeholders to allow effective collaboration and negotiation. How has the pharmaceutical reimbursement system in the Netherlands changed over the last few years? To start…

manufacturing The managing director of Ejder Kimya, Pervin Ejder explains how the landscape for API and raw materials suppliers has evolved in Turkey, and how the company has pivoted into more value added and total packaged solutions to accommodate changing market dynamics. As an introduction for our readers, Pervin, can you…

Turkey Recep Altekin, the general manager of MT Sağlik – market leader in Turkey for blood glucose monitoring systems and diabetes test strips by volume – tells PharmaBoardroom about his company’s impact on the Turkish medical device industry, and the value-added solutions that come packaged under the MT umbrella. Can you break…

South Africa   The country president of Novartis South Africa reveals how Novartis has recently moved to new premises, demonstrating a clear commitment to continue investing in the country; why South Africa has been chosen as the company´s hub for Africa, and how they have consistently been selected as one the best…

Holland In a market under strong pressures to contain costs, launching innovative products in a crowded market can be a challenge. Novo Nordisk GM Sanne Groenemeijer believes his organization’s willingness to try various solutions has helped them to maintain their dominant position as the market leader in diabetes. Since you took…

life sciences John Taboas is the president of Biopharma Consulting Services (BCS), a leader in visual inspection and other validation and engineering services. Here he tells PharmaBoardroom how the company is working to position Puerto Rico as a hub for subject matter experts in visual inspection, with a new training facility and inspection…

pharmaceuticals Dr Martin Favle, Chairman of Bogin – the Dutch Generic Medicine Industry Association, representing the interests of the generic medicines industry in the Netherlands – shares his fears about slow growth in the Dutch generics market and the state of the biosimilars market. You were quoted in the media last year saying ‘2014 was a…

marketing Ivelisse Casillas, founder of PharMaCon, Inc. talks about the challenges of marketing and advertising pharmaceuticals products in Puerto Rico. She founded the company in 2000 to provide advertising, legal and medical expertise to the sector. What are the main advertising challenges that your clients face with which you can help them? The biggest…

Turkey PharmaBoardroom talked to Sr. Managing Director of Medtronic Turkey, Ayhan Ozturk about improving patient outcomes, how the company introduced a whole new standard on integrated healthcare, and their recent USD $25 million investment in a training facility.  Medtronic recently invested USD $25 million in a state-of-the-art training facility/Center of Innovation, which opened…

universal healthcare Berlin Pharmaceutical Industry’s CEO, Amal Naj, explains how he has grown the company, its next regional and medical targets, and his vision for its future. What has led to Berlin Pharmaceutical’s success over the last five years?    In 2010, the market was going through a major transition due to the progressive…